May 14, 2020
FDA accelerates development of COVID-19 prevention, treatment options
Editor's Note
The Food & Drug Administration on May 11 took new actions to accelerate the development of novel prevention and treatment options for COVID-19.
The agency is providing guidance documents to make the process for submitting applications to initiate studies for new drugs and biological products more efficient.
The documents also outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these products for COVID-19.
Free Daily News
- Nurses top Gallup’s most trusted professions list as other healthcare roles decline
- Study: Adjusting Caprini score may improve perioperative VTE risk prediction for Blacks, Latinos
- HIPAA security standard update sparks debate over cost, feasibility, patient safety
- Wildfire smoke poses long-term health threats
- Health data inaccuracies cost millions, threaten care quality
- Healthcare employment up in December
- Hospital M&A trends report reveals financial distress, market reorganization
- Study: Patient care experience declined after private equity hospital acquisitions
- Report: Medical student distress rises amid overall healthcare burnout improvement
- Prosthetic insurance coverage disparities persist despite legal protections
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement